DDInter1042 DDInter1175
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
Methotrimeprazine {u} (Compound) resembles {v} (Compound) Moricizine
Methotrimeprazine {u} (Compound) resembles {v} (Compound) Aceprometazine
Methotrimeprazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Methotrimeprazine {u} (Compound) binds {v} (Gene) ADRA1D
Methotrimeprazine {u} (Compound) upregulates {v} (Gene) CNPY3
Methotrimeprazine {u} (Compound) downregulates {v} (Gene) TXNDC9
Methotrimeprazine {u} (Compound) causes {v} (Side Effect) Urinary retention
Methotrimeprazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Methotrimeprazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium carbonate
Methotrimeprazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Methotrimeprazine (Compound) resembles Moricizine (Compound)
Methotrimeprazine (Compound) resembles Aceprometazine (Compound)
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Methotrimeprazine (Compound) binds ADRA1D (Gene)
Methotrimeprazine (Compound) upregulates CNPY3 (Gene)
Methotrimeprazine (Compound) downregulates TXNDC9 (Gene)
Methotrimeprazine (Compound) causes Urinary retention (Side Effect)
Methotrimeprazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Methotrimeprazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate